Spiro J D, Spiro R H
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York.
Arch Otolaryngol Head Neck Surg. 1989 Oct;115(10):1186-9. doi: 10.1001/archotol.1989.01860340040013.
A retrospective analysis of 162 patients with carcinoma of the tonsillar fossa treated between 1969 and 1983 was undertaken. Of these patients, 117 were previously untreated; 11 had stage I, carcinoma, 24 had stage II, 40 had stage III, and 42 had stage IV. Combination therapy was utilized in 29% of patients with stage II disease, 40% of patients with stage III disease, and 67% of patients with stage IV disease. The three-year determinate "cure" rates were 89%, 83%, 58%, and 49% for stages I through IV, respectively. Only 22% of the previously treated patients were salvaged. Complications occurred in 36% of the previously treated patients and 18% of the previously untreated patients. Since our previous report, survival has improved, whereas operative mortality has decreased. We are unable to demonstrate a significant survival advantage when surgery and radiotherapy were used in combination.
对1969年至1983年间接受治疗的162例扁桃体窝癌患者进行了回顾性分析。在这些患者中，117例此前未接受过治疗；11例为I期癌，24例为II期，40例为III期，42例为IV期。II期疾病患者中有29%、III期疾病患者中有40%、IV期疾病患者中有67%采用了联合治疗。I至IV期的三年确定性“治愈”率分别为89%、83%、58%和49%。此前接受过治疗的患者中只有22%得到挽救。此前接受过治疗的患者中有36%发生并发症，此前未接受过治疗的患者中有18%发生并发症。自我们此前的报告以来，生存率有所提高，而手术死亡率有所下降。我们无法证明手术和放疗联合使用时具有显著的生存优势。
